**HER2 Testing Market Development Plans 2036**

Research Nester’s recent market research analysis on **“[HER2 Testing Market](https://www.researchnester.com/reports/her2-testing-market/5626): Global Demand Analysis & Opportunity Outlook 2036”** delivers a detailed competitors analysis and a detailed overview of the global HER2 testing** market in terms of market segmentation by technique, cancer type, end users and by region. 

**Rising Prevalence of Gastric and Breast Cancer to Promote Global Market Share of HER2 Testing Market**

The global HER2 testing** market is estimated to grow majorly on account of the rising incidences of breast and gastric cancer globally. Breast cancer is the most commonly diagnosed cancer among women in the world. In the year 2020, almost 2.3 million new cases of breast cancer and 685,100 deaths occurred globally. Other than this, rising gastric cancer is also responsible for the growth of the market. In 2023, almost 26,000 people in the United States were diagnosed with stomach cancer, and globally around 769,000 deaths were attributed to gastric cancer in year 2020. Other than this, the surge in the importance of personalized medicine is expected to augment the growth of the global HER2 testing** market. The increased awareness, improved diagnostic and early detection methods are driving the global HER2 testing** market growth. 

**Request Free Sample Copy of this Report @ <https://www.researchnester.com/sample-request-5626>** 

Some of the major growth factors and challenges that are associated with the growth of the global HER2 testing** market are:

**Growth Drivers:**

- Rising Healthcare Awareness Among the Population
- Increasing Importance of Personalized Medicine   

**Challenges:**

Immoderate prices for HER2 testing, lack of skilled specialists, and early patent expiration are some of the major factors anticipated to hamper the global market size of global HER2 testing** market.

By cancer type, the global HER2 testing** market is segmented into breast cancer, gastric cancer, bladder cancer, and ovarian cancer. Out of these, the breast cancer segment is projected to hold the maximum share of almost 40% during the forecast period. It has been estimated that almost 5 in 1000 women have breast cancer. There is a rising awareness in the women for the screening of breast cancer, as almost 76% of females aged between 51-75 years got cancer screening in the year 2020. A portion of breast cancer shows HER2 overexpression, demonstrating the importance of HER2-targeted therapies a pivotal component of treatment techniques. 

By region, the Europe HER2 testing** market is to generate the highest revenue by the end of 2036. The growth of the HER2 testing** market in the region is driven by the rise in incidences of breast cancer. The breast cancer is the most common in women in Europe region with a projected incidence of 576,310 in the year 2020. Other than this, the presence of large base of market players in the region is also fueling the HER2 testing** market growth during the forecasted period. 

This report also provides the existing competitive scenario of some of the key players of the HER2 Testing Market which includes company profiling of Agilent Technologies, Inc, Thermo Fisher Scientific, Roche, Empire Genomics Inc, Abnova Corporation, Eli Lilly and Company, Oxford Gene Technology IP Limited, Genetech, Genemed Technolgies Inc, PERKINELMER Inc, Daiichi Sankyo Co., Ltd, CHUGAI PHARMACEUTICALS CO., LTD, EPS Corporation, Takeda Pharmaceuticals Co Ltd, Otsuka Holdings Co Ltd. and others.**      

**Request for customization @ <https://www.researchnester.com/customized-reports-5626>**  

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

**Contact for more Info:**

**AJ Daniel**

**Email: [info@researchnester.com**](mailto:info@researchnester.com)**

**U.S. Phone: +1 646 586 9123** 

**U.K. Phone: +44 203 608 5919**

